Pages that link to "Q36187491"

The following pages link to Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota (Q36187491):

Displaying 50 items.

• Respiratory Microbiome of New-Born Infants (Q26768244) (← links)
• New Technologies for Studying Biofilms (Q26782595) (← links)
• Republished: Respiratory microbiota: addressing clinical questions, informing clinical practice (Q26797508) (← links)
• The lung microbiome after lung transplantation (Q26825397) (← links)
• The pediatric microbiome and the lung (Q26851334) (← links)
• Vaccines for Pseudomonas aeruginosa: a long and winding road (Q26852817) (← links)
• The lung microbiome in 2015: a window on chronic lung diseases (Q28086865) (← links)
• Effects of Propidium Monoazide (PMA) Treatment on Mycobiome and Bacteriome Analysis of Cystic Fibrosis Airways during Exacerbation (Q28584597) (← links)
• Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome (Q28829667) (← links)
• Bdellovibrio bacteriovorus directly attacks Pseudomonas aeruginosa and Staphylococcus aureus Cystic fibrosis isolates (Q30579959) (← links)
• Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic data (Q30641042) (← links)
• The role of the bacterial microbiome in lung disease (Q33554623) (← links)
• The microbiome of the lung and its extracellular vesicles in nonsmokers, healthy smokers and COPD patients. (Q33646225) (← links)
• Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation (Q33647129) (← links)
• Cheating by type 3 secretion system-negative Pseudomonas aeruginosa during pulmonary infection. (Q33694537) (← links)
• Update in cystic fibrosis 2012. (Q33738510) (← links)
• Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections (Q33786154) (← links)
• Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets. (Q33799679) (← links)
• The development of lower respiratory tract microbiome in mice (Q33820414) (← links)
• Lung Microbiota and Its Impact on the Mucosal Immune Phenotype. (Q33833225) (← links)
• Three distinct pneumotypes characterize the microbiome of the lung in BALB/cJ mice (Q33880637) (← links)
• The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography (Q33901596) (← links)
• The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention (Q33960112) (← links)
• The role of the microbiome in exacerbations of chronic lung diseases (Q34199591) (← links)
• Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA) (Q34278502) (← links)
• The microbiome and the lung (Q34357435) (← links)
• Type VI secretion system effectors: poisons with a purpose (Q34395319) (← links)
• Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota (Q34425661) (← links)
• MetaGeniE: characterizing human clinical samples using deep metagenomic sequencing (Q34445180) (← links)
• Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma (Q34595170) (← links)
• Interpreting infective microbiota: the importance of an ecological perspective. (Q34677317) (← links)
• Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients. (Q34684122) (← links)
• Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations (Q34706914) (← links)
• The microbial community of the cystic fibrosis airway is disrupted in early life (Q34744222) (← links)
• The Composition of Microbiome in Larynx and the Throat Biodiversity between Laryngeal Squamous Cell Carcinoma Patients and Control Population (Q34793158) (← links)
• Respiratory microbiota: addressing clinical questions, informing clinical practice (Q34818539) (← links)
• Abundant DNase I-sensitive bacterial DNA in healthy porcine lungs and its implications for the lung microbiome (Q34843160) (← links)
• Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period (Q34916610) (← links)
• Microbial communities in the respiratory tract of patients with interstitial lung disease. (Q34941172) (← links)
• Severe viral respiratory infections: are bugs bugging? (Q35039520) (← links)
• Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis (Q35065959) (← links)
• Application of a neutral community model to assess structuring of the human lung microbiome (Q35072309) (← links)
• Use of denaturing high-performance liquid chromatography (DHPLC) to characterize the bacterial and fungal airway microbiota of cystic fibrosis patients. (Q35096250) (← links)
• Bacterial microbiome of lungs in COPD (Q35109946) (← links)
• Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung. (Q35124468) (← links)
• 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. (Q35235645) (← links)
• Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation (Q35326173) (← links)
• Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome (Q35568501) (← links)
• Novel microbiome-based therapeutics for chronic rhinosinusitis (Q35578935) (← links)
• Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography (Q35585116) (← links)